Alverine
As of the edition of 20 October 2026, Alverine is a small molecule: marketed, first approved in 1990 (FR); acts on HNF4A and HTR1A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1990
- Kind
- Small molecule
- Brand name
- Meteospasmyl
- First approved
- 5 June 1990 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Laboratoires Mayoly Spindler
- Registered trials
- 6, 0 stopped early
- Disease areas
- Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 3 | 0 | 1 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Laboratoires Mayoly Spindler | Lead sponsor of trials | 2007 to now |